Aliza M. Thompson, MD, MS
Aliza Thompson is a Clinical Team Leader in the Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research (CDER), at the U.S. Food and Drug Administration (FDA). Dr. Thompson joined the FDA in 2007; her team focuses on products being developed to treat renal-related indications. Dr. Thompson has served on several CDER biomarker qualification review teams and has been involved in larger efforts to define an evidentiary framework for CDER biomarker qualification. She received her medical degree from Johns Hopkins Medical School and completed her Internal Medicine and Nephrology training at Columbia University/New York-Presbyterian Hospital. She holds a Master of Science in Biostatistics/Patient Oriented Research Track from the Columbia University Mailman School of Public Health.